Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Schizophrenia Research
|
September 11, 2024
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials
William P Horan, Steven D Targum, Amy Claxton, et al.
Frontiers in Psychiatry
|
July 9, 2025
Measurement of schizophrenia symptoms through speech analysis from PANSS interview recordings
Michelle Worthington, Georgios Efstathiadis, Vijay Yadav, et al.
Clinical Pharmacokinetics
|
July 25, 2019
SAGE-217, A Novel GABA<sub>A</sub> Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
Ethan Hoffmann, George G Nomikos, Inder Kaul, et al.
JAMA Psychiatry
|
May 1, 2024
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial
Inder Kaul, Sharon Sawchak, David P Walling, et al.
The Journal of Clinical Psychiatry
|
March 6, 2025
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
Inder Kaul, Amy Claxton, Sharon Sawchak, et al.
Schizophrenia (Heidelberg, Germany)
|
November 3, 2024
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
Inder Kaul, Sharon Sawchak, Amy Claxton, et al.
Schizophrenia Research
|
March 13, 2026
Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia
Steven D Targum, Carolyn Watson, Amy Claxton, et al.
Schizophrenia Bulletin Open
|
May 22, 2026
A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction
Peter Weiden, Cory Saucier, April M Foster, et al.
Schizophrenia Bulletin Open
|
March 23, 2026
A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms
William P Horan, Cory Saucier, Peter J Weiden, et al.
The New England Journal of Medicine
|
September 5, 2019
Trial of SAGE-217 in Patients with Major Depressive Disorder
Handan Gunduz-Bruce, Christopher Silber, Inder Kaul, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Schizophrenia Research
|
September 11, 2024
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials
William P Horan, Steven D Targum, Amy Claxton, et al.
Frontiers in Psychiatry
|
July 9, 2025
Measurement of schizophrenia symptoms through speech analysis from PANSS interview recordings
Michelle Worthington, Georgios Efstathiadis, Vijay Yadav, et al.
Clinical Pharmacokinetics
|
July 25, 2019
SAGE-217, A Novel GABA<sub>A</sub> Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
Ethan Hoffmann, George G Nomikos, Inder Kaul, et al.
JAMA Psychiatry
|
May 1, 2024
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial
Inder Kaul, Sharon Sawchak, David P Walling, et al.
The Journal of Clinical Psychiatry
|
March 6, 2025
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
Inder Kaul, Amy Claxton, Sharon Sawchak, et al.
Schizophrenia (Heidelberg, Germany)
|
November 3, 2024
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
Inder Kaul, Sharon Sawchak, Amy Claxton, et al.
Schizophrenia Research
|
March 13, 2026
Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia
Steven D Targum, Carolyn Watson, Amy Claxton, et al.
Schizophrenia Bulletin Open
|
May 22, 2026
A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction
Peter Weiden, Cory Saucier, April M Foster, et al.
Schizophrenia Bulletin Open
|
March 23, 2026
A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms
William P Horan, Cory Saucier, Peter J Weiden, et al.
The New England Journal of Medicine
|
September 5, 2019
Trial of SAGE-217 in Patients with Major Depressive Disorder
Handan Gunduz-Bruce, Christopher Silber, Inder Kaul, et al.
Page
of 3